Swiss drug major Novartis’ (NOVN: VX) faced two problems yesterday, when the Japanese Ministry of Health Labor and Welfare (MHLW) filed a formal criminal complaint with the public prosecutor’s office relating to its marketing of the antihypertensive drug Diovan (valsartan), and in the USA, where it was accused of paying kickbacks to a New York pharmacy company to promote its Exjade (deferasirox), according to numerous press reports.
The case alleges that Novartis and an unspecified number of employees for allegedly misleading consumers through advertisements that used research that the MHLW said was altered to support the benefits of Diovan—the first time criminal charges have been sought in such a case, according to a Wall Street Journal report. The research was conducted by several Japanese universities, some of which later found that the results had been falsified, exaggerating Diovan's effectiveness
Company acknowledges improper behaviour by an employee
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze